Adial Pharmaceuticals, Inc.

NASDAQ: ADIL · Healthcare · Biotechnology

PublicHQ Charlottesville, VACIK 0001513525Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 36DQ —GM —SS 31

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ workforce scale, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$8.0M

Employees

Market cap

$2.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$8.0M-$8.0M2025

Operating income-$7.8M-$7.8M2025

Total assets$6.7M$6.7M2025

Liabilities$1.4M$1.4M2025

Equity$5.3M$5.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Adial Pharmaceuticals, Inc. earned -$8.0M in FY2025 net income.

Peers · Healthcare

Hypha Labs, Inc.35D InMed Pharmaceuticals Inc.45D Hi-Great Group Holding Company25D Vaccinex, Inc.——

Key facts

CEOCary John Claiborne

SectorHealthcare

IndustryBiotechnology

HeadquartersCharlottesville, VA

ExchangeNASDAQ: ADIL

Employees5

IPO date2018-07-27

Latest filings

8-K2026-06-11 8-K2026-05-11 10-Q2026-05-08 8-K2026-04-09 8-K2026-03-06 10-K2026-03-05 8-K2026-03-03 8-K2026-02-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.